Acute hepatitis B following a switch to long-acting cabotegravir plus rilpivirine in an individual with a history of hepatitis B vaccination
Authors:
- 7 December 2025
- journal article
- case report
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (1) , 51-53
Abstract
Injectable long-acting cabotegravir plus rilpivirine (CAB+RPV LA) is an effective treatment option for people living with HIV. Unlike regimens containing tenofovir with lamivudine (3TC) or emtricitabine (FTC), it lacks therapeutic activity against the hepatitis B virus, and hepatitis B vaccination is recommended for non-immune individuals. We present a case of acute hepatitis B after switching to CAB+RPV LA in a previously vaccinated individual.Keywords
This publication has 6 references indexed in Scilit:
- Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/RilpivirineACG Case Reports Journal, 2024
- Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with menHepatology, 2023
- Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and RilpivirineOpen Forum Infectious Diseases, 2020
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionNew England Journal of Medicine, 2020
- Hepatitis B and A vaccination in HIV-infected adults: A reviewHuman Vaccines & Immunotherapeutics, 2015
- Durability of Antibody Response Against Hepatitis B Virus in Healthcare Workers Vaccinated as AdultsClinical Infectious Diseases, 2014